Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Article
PubMed
Google Scholar
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14.
Article
PubMed
Google Scholar
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–109.
Article
CAS
PubMed
Google Scholar
Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update. Hepatol Res. 2013;43(2):147–54.
Article
CAS
PubMed
Google Scholar
Villanueva A, Llovet JM. Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin Cancer Res. 2012;18(7):1824–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293–300.
Article
CAS
PubMed
Google Scholar
Yuan H, Su L, Chen WY. The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther. 2013;6:1399–416.
CAS
PubMed
PubMed Central
Google Scholar
Verdin E, Hirschey MD, Finley LW, Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci. 2010;35(12):669–75.
Article
CAS
PubMed
PubMed Central
Google Scholar
Haigis MC, Deng CX, Finley LW, Kim HS, Gius D. SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. Cancer Res. 2012;72(10):2468–72.
Article
CAS
PubMed
PubMed Central
Google Scholar
Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci U S A. 2002;99(21):13653–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schwer B, North BJ, Frye RA, Ott M, Verdin E. The human silent information regulator (sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol. 2002;158(4):647–57.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang Q, Li L, Li CY, Pei Z, Zhou M, Li N. SIRT3 protects cells from hypoxia via PGC-1alpha- and MnSOD-dependent pathways. Neuroscience. 2015;286:109–21.
Article
CAS
PubMed
Google Scholar
Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. SIRT3 and cancer: tumor promoter or suppressor? Biochim Biophys Acta. 2011;1816(1):80–8.
CAS
PubMed
PubMed Central
Google Scholar
Xiong Y, Wang M, Zhao J, Han Y, Jia L. Sirtuin 3: a Janus face in cancer (review). Int J Oncol. 2016;49(6):2227–35.
Article
CAS
PubMed
Google Scholar
Torrens-Mas M, Oliver J, Roca P, Sastre-Serra J. SIRT3: Oncogene and Tumor Suppressor in Cancer. Cancers (Basel). 2017;9(7):50.
Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D'Silva NJ, Kapila YL. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer. 2011;117(8):1670–8.
Article
CAS
PubMed
Google Scholar
George J, Nihal M, Singh CK, Zhong W, Liu X, Ahmad N. Pro-proliferative function of mitochondrial Sirtuin Deacetylase SIRT3 in human melanoma. J Invest Dermatol. 2016;136(4):809–18.
Article
CAS
PubMed
Google Scholar
Zhang B, Qin L, Zhou CJ, Liu YL, Qian HX, He SB. SIRT3 expression in hepatocellular carcinoma and its impact on proliferation and invasion of hepatoma cells. Asian Pac J Trop Med. 2013;6(8):649–52.
Article
CAS
PubMed
Google Scholar
Liu Y, Liu YL, Cheng W, Yin XM, Jiang B. The expression of SIRT3 in primary hepatocellular carcinoma and the mechanism of its tumor suppressing effects. Eur Rev Med Pharmacol Sci. 2017;21(5):978–98.
CAS
PubMed
Google Scholar
Desouki MM, Doubinskaia I, Gius D, Abdulkadir SA. Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer. Hum Pathol. 2014;45(5):1071–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dong XC, Jing LM, Wang WX, Gao YX. Down-regulation of SIRT3 promotes ovarian carcinoma metastasis. Biochem Biophys Res Commun. 2016;475(3):245–50.
Article
CAS
PubMed
Google Scholar
Yu W, Denu RA, Krautkramer KA, Grindle KM, Yang DT, Asimakopoulos F, Hematti P, Denu JM. Loss of SIRT3 provides growth advantage for B cell malignancies. J Biol Chem. 2016;291(7):3268–79.
Article
CAS
PubMed
Google Scholar
Song CL, Tang H, Ran LK, Ko BC, Zhang ZZ, Chen X, Ren JH, Tao NN, Li WY, Huang AL, et al. Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3beta/BCL2-associated X protein-dependent apoptotic pathway. Oncogene. 2016;35(5):631–41.
Article
CAS
PubMed
Google Scholar
Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, Teruya-Feldstein J, Moreira PI, Cardoso SM, Clish CB, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell. 2011;19(3):416–28.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang CZ, Liu L, Cai M, Pan Y, Fu J, Cao Y, Yun J. Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS One. 2012;7(12):e51703.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tao NN, Zhou HZ, Tang H, Cai XF, Zhang WL, Ren JH, Zhou L, Chen X, Chen K, Li WY, et al. Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway. Oncotarget. 2016;7(31):50117–30.
PubMed
PubMed Central
Google Scholar
Ramesh S, Govindarajulu M, Lynd T, Briggs G, Adamek D, Jones E, Heiner J, Majrashi M, Moore T, Amin R, et al. SIRT3 activator Honokiol attenuates beta-amyloid by modulating amyloidogenic pathway. PLoS One. 2018;13(1):e0190350.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pillai VB, Kanwal A, Fang YH, Sharp WW, Samant S, Arbiser J, Gupta MP. Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. Oncotarget. 2017;8(21):34082–98.
Article
PubMed
PubMed Central
Google Scholar
Lee M, Jeon JY, Neugent ML, Kim JW, Yun M. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma. Clin Exp Metastasis. 2017;34(3–4):251–60.
Article
CAS
PubMed
Google Scholar
Lee M, Marinoni I, Irmler M, Psaras T, Honegger JB, Beschorner R, Anastasov N, Beckers J, Theodoropoulou M, Roncaroli F, et al. Transcriptome analysis of MENX-associated rat pituitary adenomas identifies novel molecular mechanisms involved in the pathogenesis of human pituitary gonadotroph adenomas. Acta Neuropathol. 2013;126(1):137–50.
Article
CAS
PubMed
PubMed Central
Google Scholar
Heffelfinger SC, Hawkins HH, Barrish J, Taylor L, Darlington GJ. SK HEP-1: a human cell line of endothelial origin. In Vitro Cell Dev Biol. 1992;28A(2):136–42.
Article
CAS
PubMed
Google Scholar
Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sanchez P, Nguyen CB, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017;66(7):1286–96.
Article
CAS
PubMed
Google Scholar
Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Grana X, Knudsen ES. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 2010;138(5):1920–30.
Article
CAS
PubMed
Google Scholar
Ezhevsky SA, Nagahara H, Vocero-Akbani AM, Gius DR, Wei MC, Dowdy SF. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci U S A. 1997;94(20):10699–704.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010;17(1):41–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang JX, Yi Y, Li YW, Cai XY, He HW, Ni XC, Zhou J, Cheng YF, Jin JJ, Fan J, et al. Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection. BMC Cancer. 2014;14:297.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang Y, Cao Y, Chen L, Liu F, Qi Z, Cheng X, Wang Z. Cryptotanshinone suppresses cell proliferation and glucose metabolism via STAT3/SIRT3 signaling pathway in ovarian cancer cells. Cancer Med. 2018;7(9):4610–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang S, Li J, Xie J, Liu F, Duan Y, Wu Y, Huang S, He X, Wang Z, Wu X. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin beta4/SNAI1/SIRT3 signaling pathway. Oncogene. 2018;37(30):4164–80.
Article
CAS
PubMed
Google Scholar
Xiang XY, Kang JS, Yang XC, Su J, Wu Y, Yan XY, Xue YN, Xu Y, Liu YH, Yu CY, et al. SIRT3 participates in glucose metabolism interruption and apoptosis induced by BH3 mimetic S1 in ovarian cancer cells. Int J Oncol. 2016;49(2):773–84.
Article
CAS
PubMed
Google Scholar
Yadav V, Burke TF, Huber L, Van Horn RD, Zhang Y, Buchanan SG, Chan EM, Starling JJ, Beckmann RP, Peng SB. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014;13(10):2253–63.
Article
CAS
PubMed
Google Scholar
Naz S, Sowers A, Choudhuri R, Wissler M, Gamson J, Mathias A, Cook JA, Mitchell JB. Abemaciclib, a selective CDK4/6 inhibitor, enhances the Radiosensitivity of non-small cell lung Cancer in vitro and in vivo. Clin Cancer Res. 2018;24(16):3994–4005.
Article
CAS
PubMed
PubMed Central
Google Scholar
Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.
Article
PubMed
PubMed Central
CAS
Google Scholar
Carnevale I, Pellegrini L, D'Aquila P, Saladini S, Lococo E, Polletta L, Vernucci E, Foglio E, Coppola S, Sansone L, et al. SIRT1-SIRT3 Axis regulates cellular response to oxidative stress and Etoposide. J Cell Physiol. 2017;232(7):1835–44.
Article
CAS
PubMed
Google Scholar
Jablonska B, Gierdalski M, Chew LJ, Hawley T, Catron M, Lichauco A, Cabrera-Luque J, Yuen T, Rowitch D, Gallo V. Sirt1 regulates glial progenitor proliferation and regeneration in white matter after neonatal brain injury. Nat Commun. 2016;7:13866.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lee JH, Park JY, Kim DY, Ahn SH, Han KH, Seo HJ, Lee JD, Choi HJ. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int. 2011;31(8):1144–9.
Article
CAS
PubMed
Google Scholar